William Blair analyst Margaret Kaczor has maintained their bullish stance on GKOS stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Margaret Kaczor has given her Buy rating due to a combination of factors that highlight Glaukos’s potential for long-term growth. A key element in her analysis is the promising outlook of the iDose product, which is expected to drive significant revenue growth. Despite current challenges with U.S. stent sales, the company’s strong pipeline and durable margin profile are anticipated to offset these headwinds.
Furthermore, the progress in reimbursement discussions with Medicare Administrative Contractors (MACs) is seen as a positive development. Glaukos’s management is optimistic about achieving their 2025 iDose revenue guidance without additional coverage wins, although they expect further coverage to be secured. The increasing integration of iDose procedures with cataract surgeries, free from certain restrictions, also supports the favorable long-term prospects for Glaukos.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $115.00 price target.